Profile data is unavailable for this security.
About the company
Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
- Revenue in EUR (TTM)2.28m
- Net income in EUR-29.35m
- Incorporated--
- Employees174.00
- LocationPhilogen SpAVia Bellaria, 35SOVICILLE 53018ItalyITA
- Phone+39 577206941
- Fax+39 57742151
- Websitehttps://www.philogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergy Therapeutics plc | 64.21m | -60.54m | 310.33m | 635.00 | -- | 9.73 | -- | 4.83 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Valneva SE | 158.54m | -7.42m | 392.26m | 695.00 | -- | 1.54 | 9.02 | 2.47 | -0.057 | -0.057 | 1.13 | 1.56 | 0.3057 | 2.03 | 4.24 | 231,777.80 | -1.43 | -15.39 | -2.09 | -25.06 | 38.58 | 35.94 | -4.68 | -34.95 | 2.25 | 2.06 | 0.4806 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Puretech Health PLC | 436.70k | -76.95m | 454.90m | 90.00 | -- | 1.54 | -- | 1,041.69 | -0.2328 | -0.2328 | 0.0013 | 1.02 | 0.0007 | -- | 0.2252 | 4,024.44 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Oxford BioMedica plc | 117.29m | -171.23m | 526.80m | 834.00 | -- | 6.56 | -- | 4.49 | -1.44 | -1.44 | 0.9642 | 0.6292 | 0.3012 | 4.09 | 4.21 | 136,252.10 | -51.98 | -19.60 | -66.85 | -24.68 | 36.74 | 50.74 | -172.59 | -44.38 | 2.07 | -12.47 | 0.6077 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Basilea Pharmaceutica AG Allschwil | 158.79m | -694.72k | 592.18m | 156.00 | -- | 30.47 | 484.12 | 3.73 | -0.2814 | -0.2814 | 11.54 | 1.38 | 0.7118 | 1.22 | 4.40 | 1,013,755.00 | -0.3114 | -1.86 | -0.4156 | -2.99 | 76.57 | 83.45 | -0.4375 | -2.99 | 3.27 | -1.38 | 0.8508 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Philogen SpA | 2.28m | -29.35m | 599.48m | 174.00 | -- | 10.89 | -- | 262.47 | -0.7301 | -0.7301 | 0.0568 | 1.88 | 0.0191 | 5.55 | 1.57 | 14,275.00 | -24.49 | -7.32 | -27.75 | -8.36 | -564.19 | 32.04 | -1,285.03 | -58.66 | 5.02 | -- | 0.155 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Abivax SA | 0.00 | -177.43m | 608.26m | 62.00 | -- | 4.78 | -- | -- | -3.20 | -3.20 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -77.89 | -65.49 | -107.73 | -97.67 | -- | -- | -- | -- | -- | -110.67 | 0.4334 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Formycon AG | 60.80m | 63.90m | 835.17m | 239.00 | 11.83 | 1.45 | 12.66 | 13.74 | 4.00 | 4.00 | 3.64 | 32.64 | 0.0654 | 34.46 | 1.55 | 255,462.20 | 6.87 | 5.87 | 7.37 | 6.33 | 12.46 | 28.54 | 105.09 | 39.76 | 2.06 | -- | 0.0185 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| BioArctic AB | 25.82m | -7.61m | 888.69m | 96.00 | -- | 13.30 | 218.61 | 34.43 | -0.9972 | -0.9972 | 3.39 | 10.52 | 0.2699 | -- | -- | 3,401,659.00 | -7.96 | 2.24 | -8.90 | 2.56 | 88.22 | 86.52 | -29.49 | 9.76 | -- | -- | 0.0604 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
Data as of Nov 08 2024. Currency figures normalised to Philogen SpA's reporting currency: Euro EUR
6.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fideuram Asset Management SGR SpAas of 31 Oct 2024 | 520.63k | 1.78% |
| CARTHESIO SAas of 30 Jun 2024 | 350.98k | 1.20% |
| Ersel Asset Management SGR SpAas of 30 Jun 2024 | 248.00k | 0.85% |
| Azimut Capital Management SGR SpAas of 31 Oct 2024 | 157.93k | 0.54% |
| Schroder Investment Management Ltd.as of 30 Jun 2024 | 141.03k | 0.48% |
| Mediolanum Gestione Fondi SGRpAas of 28 Jun 2024 | 134.13k | 0.46% |
| Arca Fondi SGR SpAas of 30 Sep 2024 | 102.03k | 0.35% |
| Eurizon Capital SGR SpAas of 29 Dec 2023 | 76.91k | 0.26% |
| Aramea Asset Management AGas of 30 Jun 2022 | 40.00k | 0.14% |
| Amundi Asset Management SA (Investment Management)as of 02 Oct 2024 | 38.97k | 0.13% |
More ▼
Data from 28 Jun 2024 - 06 Nov 2024Source: FactSet Research Systems Inc.
